Tyrosine kinase inhibitors (TKIs) that target the fms-like tyrosine kinase 3 (FLT3) receptor have demonstrated activity in patients with acute myeloid leukemia (AML) harboring activating mutations in FLT3 [1], namely, FLT3 internal tandem duplications (FLT3-ITD) in the juxtamembrane domain and FLT3 tyrosine kinase domain (FLT3-TKD) point mutations in the activation loop [2]. This evidence concerns the gene FLT3 and acute myeloid leukemia.